JP Morgan Chase
ARGS

JP Morgan Chase’s Argos Therapeutics, Inc. ARGS Stock Holding History

JP Morgan Chase’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-493
Closed -$4K – 5521
2017
Q1 		$4K Buy
+493
New +$31.2K ﹤0.01% 4917

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

JP Morgan Chase's ARGS Position: Q2 2017 in Review

JP Morgan Chase sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 493 shares — an estimated $4K sold.

JP Morgan Chase first reported a position in ARGS in Q1 2017 and held it in 1 quarter. The position peaked at $4K in Q1 2017. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

  • JP Morgan Chase reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • JP Morgan Chase sold 493 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $4K.
  • JP Morgan Chase first reported a position in Argos Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • JP Morgan Chase's Argos Therapeutics, Inc. position peaked at $4K in Q1 2017.
  • 34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on JP Morgan Chase's 13F filing for Q2 2017, filed 9 Aug 2017.